{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:59:33Z","timestamp":1785394773956,"version":"3.55.0"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Many patients show inadequate response or intolerance to conventional therapies for ulcerative colitis (UC), including 5-aminosalicylates (5-ASA), thiopurines, and corticosteroids (CS). Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We assessed efficacy and safety as a first-line advanced therapy following different scenarios of conventional treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>In the phase III, multicenter, double-blind, placebo-controlled ELEVATE UC trials, eligible patients were randomized 2:1 to etrasimod 2\u2009mg QD or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Subgroups of patients post-5-ASA failure (prespecified), post-5-ASA\/CS (post hoc), and post-thiopurine\/5-ASA\/CS (post hoc) were assessed for clinical, endoscopic, and histologic endpoints. Safety was assessed throughout the trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In ELEVATE UC 52, 74 patients (45 receiving etrasimod 2\u2009mg QD and 29 receiving placebo) had prior failure of 5-ASA only. Among these patients, a greater proportion of those treated with etrasimod versus placebo met clinical, endoscopic, and histologic endpoints at week 12 and week 52 (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01). In complementary analyses using data pooled from ELEVATE UC 52 and ELEVATE UC 12, among those exposed to 5-ASA\/CS (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009197), a greater proportion receiving etrasimod versus placebo met all clinical efficacy endpoints assessed at week 12 and week 52 (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In those exposed to thiopurine\/5-ASA\/CS (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009104), similar efficacy was observed with statistically significant differences at week 12 and numerical differences that did not reach statistical significance at week 52. Subgroup safety outcomes were similar to those in the overall population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Etrasimod is an effective first-line advanced treatment option for patients with UC early in their treatment journey, after 5-ASA, thiopurine, or CS use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT03945188, NCT03996369.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261470909","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:52:22Z","timestamp":1785145942000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program"],"prefix":"10.1177","volume":"19","author":[{"given":"David T.","family":"Rubin","sequence":"first","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie W.","family":"Lees","sequence":"additional","affiliation":[{"name":"Institute of Genetics &amp; Molecular Medicine, The University of Edinburgh, Edinburgh, UK"},{"name":"Edinburgh IBD Unit, Western General Hospital, NHS Lothian, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Baert","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, AZ Delta, Roeselare, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kudela","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Private Ltd., Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Lazin","sequence":"additional","affiliation":[{"name":"Pfizer AG, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo M.","family":"Abbatemarco","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Canada, Kirkland, QC H2V 2W6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.01.011"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.10.001"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S237653"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2019.00084"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03096-1"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab006"},{"key":"e_1_3_4_12_2","article-title":"Treatment pathways in patients with Crohn\u2019s disease and ulcerative colitis: understanding the road to advanced therapy","volume":"360","author":"Siegel CA","unstructured":"Siegel CA, Sharma D, Griffith J, et al. Treatment pathways in patients with Crohn\u2019s disease and ulcerative colitis: understanding the road to advanced therapy. Crohns Colitis 360 2024; 6: otae040.","journal-title":"Crohns Colitis"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00198-0"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab016"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.774"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.1256"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae079"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00672-5"},{"key":"e_1_3_4_21_2","first-page":"417","article-title":"Pregnancy outcomes in the etrasimod clinical programme. 32nd United European Gastroenterology Week","volume":"2024","author":"Gesce KB","year":"2024","unstructured":"Gesce KB, Chaparro M, Abreu MT, et al. Pregnancy outcomes in the etrasimod clinical programme. 32nd United European Gastroenterology Week 2024. United Eur Gastroenterol J 2024; 12(S8): 417.","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.02.016"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2018.08.018"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac024"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0930"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2026.05.024"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000128"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.01.013"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001134776.45672.fd"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab016"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa032"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02605-y"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad106"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000808"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261470909","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261470909","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261470909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:17:53Z","timestamp":1785392273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261470909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["10.1177\/17562848261470909"],"URL":"https:\/\/doi.org\/10.1177\/17562848261470909","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261470909"}}